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Fabry disease is an X-linked lysosomal disease caused by deficiency of α-galactosidase, in which early diagnosis 
may be missed due to the wide variety of clinical symptoms presenting during disease progression. A 13 year-old 
boy visited our pain clinic complaining of pricking and burning pain in the toe tips of both feet. Continuous 
epidural infusion for pain management was performed because of oral analgesics ineffectiveness. The patient 
underwent  α-galactosidase A (GLA) enzyme analysis based on the clinical impression of Fabry disease from 
pain with a peripheral neuropathic component and history of anhidrosis. He was diagnosed with Fabry disease 
after confirming mutation of the GLA gene through a screening test of GLA activity. Enzyme replacement 
therapy was initiated and pain was tolerated with oral analgesics. (Korean  J  Pain  2010;  23:  207-210)
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    Fabry disease is an X-linked disorder characterized by 
deficient activity of the lysosomal hydrolase, α-galacto-
sidase  A  (GLA)  [1].  Affected  patients  cannot  effectively 
metabolize membrane glycosphingolipids, particularly glo-
botriaosylceramide (GL-3), resulting in its accumulation in 
the vascular endothelium of various tissues [2]. Accumu-
lation of GL-3 eventually leads to life-threatening renal, 
cardiac, and cerebrovascular complications, typically dur-
ing the third to fifth decades of life [2,3]. The incidence 
o f  F a b r y  d i s e a s e  h a s  b e e n  e s t i m a t e d  t o  r a n g e  f r o m  
1/40,000 to 1/117,000 live births for males [4]. In male pa-
tients with the classic phenotype, onset of symptoms oc-
curs in childhood or adolescence with chronic paresthesia 
and episodes of severe acral and/or abdominal pain, heat 
intolerance, lack of sweating, and angiokeratomas [2,5]. 
We present a 13 year-old boy with periodic intractable pain 
in the toe tips of both feet. Pain was managed with con-
tinuous epidural infusion after a diagnosis of Fabry disease. 
CASE  REPORT
    A 13 year-old boy visited our pain clinic complaining 
of pricking and burning pain in both toe tips. His caregiver 
stated that he had complained of intermittent pain in both 208 Korean J Pain Vol. 23, No. 3, 2010
feet since he was in early elementary school. He had vis-
ited doctors of various specialties, including a psychiatrist; 
however, they were unable to explain the exact cause of 
p a i n .  H e  h a d  b e e n  p r e s c r i b e d  a n a l g e s i c s  s u c h  a s  n o n - 
steroidal  anti-inflammatory  drugs  for  pain  control.  His 
pain had been aggravated with physical activity or hot en-
vironments so that he could not engage in physical activity 
at school or otherwise. 
    The patient initially presented with persistent pain in 
both toe tips, which alternated irregularly between toler-
ability for a couple days or weeks and intractability. In the 
past five months, the pain had worsened and could not be 
controlled with oral medications. He did not show any ab-
normality in his lower extremities according to sensory and 
motor tests. Magnetic resonance imaging (MRI) of his foot 
and lumbar spine was taken 2 years ago with no specific 
findings. Routine blood tests were normal. X-rays of the 
l u m b a r  r e g i o n  a n d  b o t h  f e e t  s h o w e d  o s t e o p e n i a ,  a n d  a 
b o n e  s c a n  r e v e a l e d  i n c r e a s e d  u p t a k e  o f  t h e  r i g h t  
calcaneus.  Electromyogram  (EMG)  and  nerve  conduction 
velocity (NCV) of his lower extremities were normal. He was 
considered  to  have  peripheral  neuropathy  even  though 
EMG and NCV were normal, because of the characteristics 
of his pain. The patient's parents also reported a history 
of anhidrosis. Based on pain characteristics and anhid-
rosis, Fabry disease was diagnosed and the patient was 
prescribed gabapentin (GABAPENTIN
Ⓡ, Dong-A) for pain 
control. 
    Because toe pain persisted for 2 days despite the 
medication, the patient underwent epidural injection with 
5 ml of 0.3% mepivacain (MEPIV ACAIN
Ⓡ, HANA) with 50 
μg of fentanyl (FENTANYL CITRATE
Ⓡ, HANA). However, 
the patient was pain free for just a few hours afterward 
before pain recurred. Following 2 more epidural injections, 
continuous epidural infusion with mepivacine and fentanyl 
was commenced after informed consent, and he was hos-
pitalized  and  evaluated  for  Fabry  disease.  The  Genetics 
department was consulted and a test for Fabry disease was 
done, with GL-3 levels in plasma and urine found to be 
10 times higher than normal. The GLA activity test, the 
hallmark enzyme test for Fabry disease, revealed no en-
zyme activity. Mutation analysis of the GLA gene was per-
formed and mutation p.W349X in exon 7 was discovered, 
resulting in a diagnosis of Fabry disease. The patient's in-
t e r m i t t e n t  b l u r r e d  v i s i o n  a n d  k i d n e y  f u n c t i o n  w e r e  a l s o 
evaluated. No abnormalities in a 24-hour urine test were 
f o u n d ,  h o w e v e r  t u r b i d i t y  i n  t h e  r e t r o l e n t a l  r e g i o n  w a s  
found. Electrocardiogram (EKG) and echocardiogram was 
normal. After a screening test, his mother and younger 
sister were found to be carriers of the mutation, but with 
no major organ dysfunction. Close observation of the two 
was planned. 
    The patient experienced tolerable pain with six days of 
continuous epidural infusion; therefore, it was stopped. The 
Genetics department started enzyme replacement therapy 
( E R T )  w i t h  1  m g / k g  o f  a g a l s i d a s e  b e t a  ( F a b r a z y m e
Ⓡ, 
Genzyme, U.S.A) 3 weeks after Fabry disease was regis-
tered as a rare disease. During a 4-hour infusion of agal-
sidase beta, there were no side effects such as anaphy-
laxis, skin reaction, fever, chest tightness, etc. Phenytoin 
(PHENYTOIN
Ⓡ,  B K W )  2 0 0  m g / d a y  a n d  c a r b a m a z e p i n e  
(CARBAMAZEPIN
Ⓡ, DAEHWA) 400 mg/day were prescribed 
for  pain  in  combination  with  ERT.  Toe  pain  was  con-
sistently mild to moderate with the pain medication and 
ERT was performed 5 times over 8 months. Pain medi-
cation was tapered to phenytoin 100 mg/day and carba-
mazepine 200 mg/day as pain gradually decreased. Future 
treatment plans from the Genetics department are ERT 
twice a month, with regular check-ups of urine and serum 
GL-3 levels and kidney function every 3 months, and eval-
uation of EKG and echocardiogram annually. 
DISCUSSION
    Fabry disease has a variety of symptoms and signs, 
including pain attacks and life-threatening major organ 
f a i l u r e  r e s u l t i n g  f r o m  a c c u m u l a t i o n  o f  G L 3  i n  t h e  
endothelium. Early treatment of Fabry disease may prevent 
or delay debilitating conditions, however, lack of disease 
awareness may delay correct diagnosis. 
    Ramaswami et al. [5] reported the most frequent early 
clinical  manifestations  were  neurological  and  gastro-
intestinal symptoms, and were documented in about 80% 
and 60% of patients, respectively. Neurological symptoms 
include acroparesthesia, generalized pain, altered temper-
ature  sensitivity  and  dyshidrosis.  Abdominal  pain  is  the 
most common gastrointestinal manifestation. Ries et al. [6] 
identified 35 pediatric Fabry disease patients (range, 1-21 
years; mean, 12.6 years) in 25 families and reported that 
cornea verticillata was found in 73%; headache, tinnitus, 
recurrent vertigo, diminished level of activity, fatigue, or 
depression were identified in 67%; and angiokeratoma was KB Park, et al / Diagnosis of Fabry Disease 209
found in 53% of these patients. In addition to the above 
symptoms, there have been reports of Fabry disease pre-
senting  with:  claudication,  Raynaud's  phenomenon,  pe-
ripheral  edema,  lymphoedema,  depression,  behavioural 
problems and anxiety, arrhythmia, chest pain, dyspnea, 
left ventricular hypertrophy, palpitations, syncope, valvular 
heart disease including mitral valve prolapse, systolic mur-
murs, and frequent infections [5]. 
    Fabry disease might be misdiagnosed or diagnosed 
late because of its varying symptoms and signs. It should 
be suspected, however, if any of the above symptoms are 
present in young male patients. Family history with respect 
to renal, cardiovascular, and cerebrovascular events can 
also be very helpful in diagnosis [7]. In our case, the pa-
tient complained of intermittent pain in both feet since he 
was in early elementary school, and his mother experi-
enced similar symptoms since junior high school. In addi-
tion,  our  patient  experienced  acroparesthesia,  burning 
pain and anhydrosis. 
     Fabry disease is a progressive condition with life- 
threatening renal, cardiac and cerebrovascular manifes-
tations that generally develope during the third or fourth 
decade of life [8]. Wozniak et al. [9] collected data of hos-
pitalized men, aged 15 to 49 years, with a first cerebral 
inf ar ction id en tified by dischar ge surv eillance. The y d e-
s c r i b e d  0 . 6 5 %  o f  p a t i e n t s  w i t h  c r y p t o g e n i c  s t r o k e s  h a d 
previously not been diagnosed with Fabry disease. Kotanko 
et al. [10] reported a nationwide screening for Fabry dis-
ease of 2,480 Austrian dialysis patients in 2002 and 2003, 
resulting in a prevalence of 0.161%. Occasionally, signs of 
major organ involvement have been found at an early age, 
as reported by Ries et al. [6]. Early diagnosis of Fabry dis-
ease is crucial in early therapeutic intervention to retard 
the life-threatening progression of the disease. 
    Ram asw am i et al. [5] reported an approxim ately 3-y ear 
delay between the appearance of symptoms and diagnosis 
i n  a  F a b r y  o u t c o m e  s u r v e y  o f  1 1  E u r o p e a n  c o u n t r i e s .  
Difficulty in diagnosis of Fabry disease is due to its rarity 
and variety of symptoms and signs, which can lead to mis-
diagnosis [6]. Of special note, acroparaethesia and dyshid-
rosis, as in our patient, may be the most common early 
presentation of Fabry disease, and practitioners should be 
careful  when  evaluating  patients  with  these  symptoms. 
Marchesoni et al. [11] reported on the most frequent diag-
nostic errors in 45 consecutive symptomatic patients with 
confirmed Fabry disease - the most common misdiagnosis 
being rheumatic fever. Sometimes, pain attacks in Fabry 
disease are accompanied by fever, malaise, and elevated 
erythrocyte  sedimentation  rate  [12];  however,  rheumatic 
fever  is  characterized  by  migratory  polyarthritis  [13]. 
Furthermore, they reported abdominal pain was the second 
m o s t  c o m m o n  r e a s o n  f o r  c o n s u l t a t i o n  i n  p a t i e n t s  w i t h  
Fabry disease. 
    ERT f or F a bry disease has been a v aila b le in Kor ea sin ce 
2002. The beneficial effects of ERT on different organs/ 
systems have been extensively evaluated and include im-
p r o v e d  q u a l i t y  o f  l i f e  a n d  r e d u c e d  p a i n  s e v e r i t y  [ 1 4 ] .  
Hoffmann et al. [15] reported the effects of ERT on pain 
and health related quality of life in 545 patients registered 
in a Fabry disease database. They described improvements 
in Brief Pain inventory scores after 1-2 years of treatment 
with agalsidase alfa. Hoffmann et al. [16] studied the prev-
alence and effects of ERT on abdominal symptoms asso-
ciated with Fabry disease in large cohorts and concluded 
it reduced prevalence of gastrointestinal symptoms, par-
ticularly in children and male patients. ERT has shown a 
stabilization of renal function and prognosis has proven to 
be significantly better in cases of mild or moderate renal 
insufficiency from baseline [17]. Cardiac benefits have also 
been reported, including reduction in left ventricular mass 
in  patients  with  left  ventricular  hypertrophy  caused  by 
Fabry disease [18]. Wraith et al. [19] evaluated the safety 
and efficacy of agalsidase beta in children aged 8-15 years 
in an open-label study, and reported that the GL-3 accu-
m u l a t i o n  i n  d e r m a l  e n d o t h e l i u m  w a s  e f f e c t i v e l y  r e d u c e d 
with agalsidase beta (1 mg/kg) intravenous infusion every 
2 weeks for 48 weeks. Banikazemi et al. [20] found that 
agalsidase  beta  (1  mg/kg)  intravenous  infusion  twice  a 
month for up to 35 months showed slower progression of 
major organ complications compared with a placebo group. 
    In conclusion, pain practitioners should be aware of 
the variety of Fabry disease symptoms, as early diagnosis 
is essential for successful treatment.
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